# B. Infantis Supplementation to Improve Immunity in Infants Exposed to HIV

> **NCT05923333** · NA · RECRUITING · sponsor: **University of Cape Town** · enrollment: 200 (estimated)

## Conditions studied

- Hiv
- Vaccine Reaction
- Microbial Colonization
- Infant Development

## Interventions

- **DIETARY_SUPPLEMENT:** B. infantis Rosell®-33
- **DIETARY_SUPPLEMENT:** Placebo

## Key facts

- **NCT ID:** NCT05923333
- **Lead sponsor:** University of Cape Town
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-11
- **Primary completion:** 2026-06
- **Final completion:** 2027-06
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2024-08-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05923333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05923333, "B. Infantis Supplementation to Improve Immunity in Infants Exposed to HIV". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05923333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*